Prescribing SECUADO 4

To minimize skin reactions1 Erythema, pruritus, papules, discomfort, pain, edema, or irritation may occur and skin irritation may increase if SECUADO® is applied for longer than instructed or if the same site is used repeatedly Instruct patients to select a different application site each day External heat: Tell patients to avoid direct external heat sources, […]

Prescribing SECUADO 3

Patient guidance: Applying the SECUADO® transdermal patch • Patients should choose 1 application site from the approved sites shown to apply 1 patch1• The patch may be applied to the right or left side1 • Patients should be instructed to apply SECUADO® to clean, dry, and intact skin at the selected application site1• For complete […]

Clinical Evidence 4

Established safety and tolerability: IT’S ON™ Commonly observed adverse reactions (incidence ≥5% and at least twice the rate of placebo) were extrapyramidal disorder, application site reaction, and weight gain1 SECUADO® had a discontinuation rate similar to placebo1 A total of 4.9% of patients treated with SECUADO 3.8 mg/24 hours, 7.8% of patients treated with SECUADO […]

Clinical Evidence 3

Other clinical data Sublingual asenapine • The efficacy of SECUADO® was established, in part, on data from trials with the sublingual formulation of asenapine1 Maintenance of efficacy with sublingual asenapine1 Maintenance of efficacy has been demonstrated in a placebo-controlled, double-blind, multicenter, flexible dose with sublingual asenapine (5 mg or 10 mg twice daily based on […]

Clinical Evidence 2

Significant reduction in PANSS total score at week 6 (n=607)1 Both doses of SECUADO® were also statistically superior to placebo for Clinical Global Impressions – Severity (CGI-S)1 An examination of population subgroups did not reveal any clear evidence of differential responsiveness on the basis of age, sex, and/or race1 The efficacy of SECUADO® was evaluated […]


Your patients and their caregivers may find these resources helpful. Click here Mental Health America (MHA) MHA is the nation’s leading community-based nonprofit dedicated to addressing the needs of those living with mental illness and promoting the overall mental health of all Americans. 703-684-7722 National Alliance on Mental Illness (NAMI)​ NAMI envisions a world where […]

Noven C.A.N. Support 1

Noven Care Access Network (Noven C.A.N.™) can help your patients access SECUADO® The Noven Care Access Network (Noven C.A.N.™) is ready to help you and your personal support partners. Areas where Noven C.A.N. can help include: • Understanding SECUADO® coverage• Investigating the prior authorization process• Connecting you to SECUADO® information resources NOVEN C.A.N. will also help your […]

Prescribing SECUADO 2

Empower your patients with treatment they can wear Patients should change the patch and application site every 24 hours.1


Reduction of symptoms with the SECUADO® patch compared to placebo (non-medicated patch) after 6 weeks PANSS total score improvement vs placebo How might SECUADO® help? In a medical study of more than 600 adults, SECUADO® helped people living with schizophrenia manage their symptoms. At the end of this 6-week study, the symptoms of people using […]

Prescribing SECUADO 1

Dosing flexibility: IT’S ON™ Three dosing strengths, one convenient delivery form1 Patients should be started and can be maintained on a 3.8 mg/24-hour patch1 Dosage may be increased to 5.7 mg/24 hours or 7.6 mg/24 hours, if needed, after 1 week1 No adjustments needed for1: • Gender• Race• Smoking status• Renal impairmentNo food or drink […]

You are now leaving the SECUADO® (asenapine) transdermal system website and moving to an external website independently operated and not managed by Noven

The site you are about to enter is intended specifically for US healthcare professionals.

Click continue if you are a US healthcare professional.